
{
  "documentMetadata": {
    "title": "Pneumonia, Nocardia sp.",
    "lastUpdated": "2024-02-29",
    "sourceFile": "Pneumonia, Nocardia sp..pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Pneumonia in an immunocompromised host.",
        "Culture positive for Nocardia sp."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Over 40 species of Nocardia have been identified in human infections (Clin Microbiol Rev. 2006; 19:259; Clin Microbiol Rev. 2022; 35:e0002721). The more common are listed below.",
        "Nocardia nova complex",
        "Nocardia farcinica",
        "Nocardia cyriacigeorgica",
        "Nocardia brasiliensis",
        "Nocardia abscessus"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "TMP-SMX 15 mg/kg/day (dose of TMP component) IV/po divided in 2-4 doses + Imipenem-cilastatin 500 mg IV q6h x 3-4 weeks; then TMP-SMX 10 mg/kg/day IV/po divided in 2-4 doses x 3-6 months"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Imipenem-cilastatin 500 mg IV q6h + Amikacin 7.5 mg/kg IV q12h x 3-4 weeks; then TMP-SMX po"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Nocardia spp. have a propensity for CNS involvement. Brain imaging (CT or MRI) should be performed in patients with pulmonary nocardiosis.",
        "Speciation and susceptibility testing are recommended to confirm in vitro activity of antimicrobial regimen",
        "Antimicrobial susceptibilities vary among species.",
        "N. farcinica is resistant to Ceftriaxone, which should not be used in infection caused by this organism.",
        "TMP-SMX is a drug of choice for all species. Although in vitro resistance reportedly increasing (Clin Infect Dis 51:1445, 2010) unknown if this is predictive of worse outcomes and may reflect difficulty in interpretation of MIC end-points (J Clin Microbiol 50:670, 2012).",
        "Resistance to TMP/SMX, amikacin and linezolid is rare.",
        "Linezolid is highly active in vitro (Clin Microbiol Infect 17:690, 2011; Clin Microbiol Infect 12:905, 2006) and limited clinical data suggest in vivo efficacy (Open Forum Infect Dis. 2020 Mar 16;7(4):ofaa090). Duration of therapy may be limited by toxicity.",
        "Tedizolid is active in vitro and perhaps better tolerated, but efficacy not well documented, use limited to case reports (J Infect Chemother. 2022;28:1172).",
        "Other agents with in vitro activity against some species, although few efficacy data: Amoxicillin-clavulanate, Ceftriaxone, Clarithromycin, Minocycline (Clin Microbiol Infect 17:690, 2011; Clin Microbiol Infect 12:905, 2006; Medicine 88:250, 2009).",
        "If organism is sulfonamide-resistant or patient is sulfa-allergic, use Amikacin plus one of: Imipenem, Meropenem, Ceftriaxone.",
        "Duration of therapy: 3 months if patient is immunocompetent; 6 months if immunocompromised.",
        "Help Lines for susceptibility testing: Wallace Lab (+1) 903-877-7680; CDC (+1) 404-639-3158."
      ]
    }
  ]
}
